Literature DB >> 1900037

Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression.

N Esumi1, B Hunt, T Itaya, P Frost.   

Abstract

Spontaneous SP1 murine adenocarcinoma cells transfected with the murine gamma-interferon (IFN-gamma) gene expressed IFN-gamma (SP1/IFN-gamma) failed to grow in syngeneic hosts and grew in nude mice. The rejection of SP1/IFN-gamma cells was related to the amount of IFN-gamma produced and appeared to be mediated primarily by nonspecific cellular mechanisms, although some role for T-cells in the afferent arm of this response is possible. SP1 cells are H2-Kk negative but express class I antigens when producing IFN-gamma. However, class I major histocompatibility complex (MHC) expression, while likely necessary, was insufficient in itself to prevent tumor growth since secretion of greater than 64 units/ml IFN-gamma was needed to inhibit tumorigenicity while only 8 units/ml IFN-gamma could induce class I antigens. Similar results were obtained with the murine colon carcinoma CT-26, a tumor that constitutively expresses class I MHC antigens, further supporting the contention that class I MHC expression is not essential for the rejection response induced by IFN-gamma. The failure of SP1/IFN-gamma cells to protect against a challenge with parent SP1 cells argues that factors other than IFN-gamma production or class I MHC expression are needed to induce a protective response against weakly or nonimmunogenic tumor cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900037

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Reduction of tumorigenicity by an interferon-gamma-gene-transduced tumor on another syngeneic tumor in a murine model.

Authors:  Y Ichinose; T Okino; S Yamasaki; Y Moriguchi; T Sugie; L Li; S Kanaoka; N Kan; Y Watanabe; M Imamura
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Increased anti-tumor effect by a combination of HSV thymidine kinase suicide gene therapy and interferon-gamma/GM-CSF cytokine gene therapy in CT26 tumor model.

Authors:  Sung Hyun Yang; Tae Keun Oh; Seung Taik Kim
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

3.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.

Authors:  H Hock; M Dorsch; U Kunzendorf; Z Qin; T Diamantstein; T Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

4.  High-avidity T cells are preferentially tolerized in the tumor microenvironment.

Authors:  Ziqiang Zhu; Vinod Singh; Stephanie K Watkins; Vincenzo Bronte; Jennifer L Shoe; Lionel Feigenbaum; Arthur A Hurwitz
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

Review 5.  Strategies for cytokine utilisation in tumor therapy.

Authors:  F Di Pierro; F Cavallo; F Pericle; S Bertini; M Giovarelli; G Forni
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 6.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

7.  Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo.

Authors:  S M Dubinett; L Patrone; J Tobias; A J Cochran; D R Wen; W H McBride
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Immunotherapy of malignancy by in vivo gene transfer into tumors.

Authors:  G E Plautz; Z Y Yang; B Y Wu; X Gao; L Huang; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

9.  Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell.

Authors:  Su-Jin Oh; Chung-Kyu Ryu; So-Young Baek; Hyunah Lee
Journal:  Immune Netw       Date:  2011-12-31       Impact factor: 6.303

10.  Chemotherapeutic candidate inducing immunological death of human tumor cell lines.

Authors:  Su-Jin Oh; Chung-Kyu Ryu; Inhak Choi; So-Young Baek; Hyunah Lee
Journal:  Immune Netw       Date:  2012-04-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.